Acantha

Acantha Bio is a preclinical-stage biotechnology company based in San Diego, California, focused on developing next-generation conditionally active biologics for oncology. The company utilizes a proprietary protein engineering platform to design "masked" antibodies and fusion proteins that remain inert in systemic circulation but are selectively activated by proteases within the tumor microenvironment. This approach aims to enhance the therapeutic index of potent but toxic targets, such as EGFR and HER2, by minimizing off-target effects in healthy tissues. Acantha Bio's pipeline includes several programs targeting solid tumors, with the goal of providing safer and more effective treatment options for cancer patients.